Phase 2b data from EASD 2026 show the amylin-incretin combination also cut HbA1c by up to 2.9% in adults with obesity or overweight and type 2 diabetes.
|Articles|June 6, 2018
How Do Workflow Technologies Reduce IV Preparation Errors?
In this clip, Mark Neuenschwander, President of The Neuenschwander Company, discussed IV preparation errors and the importance of workflow technologies in reducing error rates.
Advertisement
At the ASHP Summer Meeting and Exhibition held this week in Denver, CO, Mark Neuenschwander, President of The Neuenschwander Company, sat down with Pharmacy Times to discuss the importance of utilizing technology in hospital settings to reduce medication errors. In this clip, Neuenschwander explains how IV workflow technologies work to reduce IV preparation error rates and increase patient safety.
Advertisement
Related to this article
fMRI data show cagrilintide-semaglutide altered brain responses to high-calorie food cues; REIMAGINE analyses point to ectopic fat and bone effects.
A Novo Nordisk–funded claims analysis of adults with type 2 diabetes found an adjusted HR of 1.06 for MACE with switching, although the findings cannot show causation.
A new analysis finds a significant weight loss edge for tirzepatide under one estimand but not another; no head-to-head trial exists at these doses.
Indirect comparison links orforglipron 17.2 mg to 1.5% more weight loss and 0.3% more A1C lowering than oral semaglutide 25 mg in adults with type 2 diabetes.
Phase 3 TRIUMPH-2 data presented at EASD show HbA1C reductions up to 1.6%, with GI effects, hypotension, and dysesthesia as key counseling points.
A behavioral walking program matched supervised aerobic training for improving asthma control in a randomized trial of physically inactive adults.
American Pharmacists Month kicked off on October 1, honoring more than 700,000 pharmacy professionals and 250 years of caring for America's communities.
Advertisement
Advertisement